These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26183688)

  • 1. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA).
    Guttmann OP; Pavlou M; O'Mahony C; Monserrat L; Anastasakis A; Rapezzi C; Biagini E; Gimeno JR; Limongelli G; Garcia-Pavia P; McKenna WJ; Omar RZ; Elliott PM;
    Eur J Heart Fail; 2015 Aug; 17(8):837-45. PubMed ID: 26183688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification of patients with left atrial appendage thrombus prior to catheter ablation of atrial fibrillation: An approach towards an individualized use of transesophageal echocardiography.
    Gunawardene MA; Dickow J; Schaeffer BN; Akbulak RÖ; Lemoine MD; Nührich JM; Jularic M; Sinning C; Eickholt C; Meyer C; Moser JM; Hoffmann BA; Willems S
    J Cardiovasc Electrophysiol; 2017 Oct; 28(10):1127-1136. PubMed ID: 28635023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ischemic Stroke in Patients With Hypertrophic Cardiomyopathy According to Presence or Absence of Atrial Fibrillation.
    Fauchier L; Bisson A; Bodin A; Herbert J; Spiesser P; Pierre B; Clementy N; Bernard A; Babuty D; Lip GYH
    Stroke; 2022 Feb; 53(2):497-504. PubMed ID: 34601900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of atrial fibrillation in hypertrophic cardiomyopathy.
    Guttmann OP; Pavlou M; O'Mahony C; Monserrat L; Anastasakis A; Rapezzi C; Biagini E; Gimeno JR; Limongelli G; Garcia-Pavia P; McKenna WJ; Omar RZ; Elliott PM;
    Heart; 2017 May; 103(9):672-678. PubMed ID: 27794017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of CHA
    Hjelholt TJ; Johnsen SP; Brynningsen PK; Pedersen AB
    J Am Geriatr Soc; 2020 Aug; 68(8):1698-1705. PubMed ID: 32294240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis.
    Rujirachun P; Charoenngam N; Wattanachayakul P; Winijkul A; Owattanapanich W; Ungprasert P
    Acta Cardiol; 2020 Dec; 75(8):724-731. PubMed ID: 31558097
    [No Abstract]   [Full Text] [Related]  

  • 7. [Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and hypertrophic cardiomyopathy].
    Liu YY; Du X; He L; Hu R; Ning M; Lyu J; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jan; 50(1):62-67. PubMed ID: 35045616
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of hypertrophic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular atrial fibrillation.
    Tsuda T; Hayashi K; Fujino N; Konno T; Tada H; Nomura A; Tanaka Y; Sakata K; Furusho H; Takamura M; Kawashiri MA; Yamagishi M;
    Heart Rhythm; 2019 Jun; 16(6):829-837. PubMed ID: 30503962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.
    Hsu JC; Huang YT; Lin LY
    Aging (Albany NY); 2020 Nov; 12(23):24219-24227. PubMed ID: 33226371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of incident atrial fibrillation in hypertrophic cardiomyopathy.
    Losi MA; Monda E; Lombardi R; Lioncino M; Canciello G; Rubino M; Todde G; Caiazza M; Borrelli F; Fusco A; Cirillo A; Perillo EF; Sepe J; Pacella D; de Simone G; Calabro P; Esposito G; Limongelli G
    Int J Cardiol; 2024 Jan; 395():131575. PubMed ID: 37951419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertrophic Cardiomyopathy in Patients with Atrial Fibrillation: Prevalence and Associated Stroke Risks in a Nationwide Cohort Study.
    Jung H; Yang PS; Sung JH; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
    Thromb Haemost; 2019 Feb; 119(2):285-293. PubMed ID: 30602200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIMI-AF score and cardiovascular events in vitamin K antagonists-naïve outpatients with atrial fibrillation.
    Pérez Cabeza AI; Bravo Marques R; Chinchurreta Capote PA; Ruiz Mateas F; Fanola CL; Rosas Cervantes G; González Correa JA; Valle Alberca A; Mesa Prado F; López Tejero S; Ruff CT
    Clin Cardiol; 2018 Sep; 41(9):1252-1258. PubMed ID: 30062699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta-analysis.
    Romero J; Cerrud-Rodriguez RC; Diaz JC; Rodriguez D; Arshad S; Alviz I; Cerna L; Rios S; Monhanty S; Natale A; Garcia MJ; Di Biase L
    J Cardiovasc Electrophysiol; 2019 Aug; 30(8):1250-1257. PubMed ID: 31257677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular remodeling in hypertrophic cardiomyopathy patients with atrial fibrillation.
    Tian H; Cui J; Yang C; Hu F; Yuan J; Liu S; Yang W; Jiang X; Qiao S
    BMC Cardiovasc Disord; 2018 Nov; 18(1):207. PubMed ID: 30390664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.
    Garg L; Gupta M; Sabzwari SRA; Agrawal S; Agarwal M; Nazir T; Gordon J; Bozorgnia B; Martinez MW
    Heart Fail Rev; 2019 Mar; 24(2):189-197. PubMed ID: 30456592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of left atrial thrombus in patients with hypertrophic cardiomyopathy and atrial fibrillation.
    Burczak DR; Scott CG; Julakanti RR; Kara Balla A; Swain WH; Ismail K; Geske JB; Killu AM; Deshmukh AJ; MacIntyre CJ; Ommen SR; Nkomo VT; Gersh BJ; Noseworthy PA; Siontis KC
    J Interv Card Electrophysiol; 2024 Jun; 67(4):731-738. PubMed ID: 37715077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.
    Guttmann OP; Rahman MS; O'Mahony C; Anastasakis A; Elliott PM
    Heart; 2014 Mar; 100(6):465-72. PubMed ID: 24014282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study.
    Wang Y; Gao W; Han X; Jiang J; Sandler B; Li X; Zema C
    J Med Econ; 2023; 26(1):1495-1506. PubMed ID: 37902966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertrophic Cardiomyopathy Predicts Thromboembolism and Heart Failure in Patients With Nonvalvular Atrial Fibrillation　- A Prospective Analysis From the Hokuriku-Plus AF Registry.
    Tsuda T; Hayashi K; Kato T; Kusayama T; Nakagawa Y; Nomura A; Tada H; Usui S; Sakata K; Kawashiri MA; Fujino N; Yamagishi M; Takamura M;
    Circ J; 2023 Nov; 87(12):1790-1797. PubMed ID: 37866911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation.
    Dominguez F; Climent V; Zorio E; Ripoll-Vera T; Salazar-Mendiguchía J; García-Pinilla JM; Urbano-Moral JA; Fernández-Fernández X; Lopez-Cuenca D; Ajo-Ferrer R; Sanz-Sanchez J; Gomez-Perez Y; López-Garrido MA; Barriales-Villa R; Gimeno JR; Garcia-Pavia P
    Int J Cardiol; 2017 Dec; 248():232-238. PubMed ID: 28811092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.